Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Naoko Usui
Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash
Therapeutic regimens containing pemetrexed (PEM) are standard chemotherapy protocols for patients with thoracic malignancies, including non-small-cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM).1–4 Grade 3 or 4 skin rash is a characteristic side effect reported in 31% of patients receiving PEM in the absence of prophylactic treatment, including steroid administration and vitamin supplementation.5 Ohe et al 6 reported that the incidences of any grade skin rash and grade 3 or...
Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash
Therapeutic regimens containing pemetrexed (PEM) are standard chemotherapy protocols for patients with thoracic malignancies, including non-small-cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM).1–4 Grade 3 or 4 skin rash is a characteristic side effect reported in 31% of patients receiving PEM in the absence of prophylactic treatment, including steroid administration and vitamin supplementation.5 Ohe et al6 reported that the incidences of any grade skin rash and grade 3 or 4...
Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash
Objective The present study aimed to retrospectively examine the effectiveness of mandatory dexamethasone (m-DEX) strictly monitored by pharmacists collaborating with medical physicians and nurses for reducing pemetrexed (PEM)-induced skin rash in patients with non-squamous non-small-cell lung cancer (ns-NSCLC).
Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash
Objective The present study aimed to retrospectively examine the effectiveness of mandatory dexamethasone (m-DEX) strictly monitored by pharmacists collaborating with medical physicians and nurses for reducing pemetrexed (PEM)-induced skin rash in patients with non-squamous non-small-cell lung cancer (ns-NSCLC).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Naoko
Contact Naoko, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack